Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GenESA system: Completed enrollment of 700 patients in Phase III trials

Gensia Inc. (GNSA)
Product: GenESA

Read the full 58 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE